Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Baron Funds, an investment management company, released its Q3 2024 investor letter. Here is what the fund said: “We ...

Meanwhile, Regeneron and Truveta said they plan to use the data in the development of new approaches for healthcare delivery and population health management. "By combining Regeneron's expertise ...

Amgen’s management commented that in the last nine weeks of 2024 alone, Pavblu generated $31 million in sales. That’s fantastic for a brand-new drug. Should Regeneron wish to compete ...

In that sense, Gilead (GILD) with lenacapavir and Regeneron (REGN) with Eylea label expansion and new formulation “theoretically have the most risk,” followed by Merck (MRK) with subcutaneous ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Full Interview Summary: Regeneron envisions DB-OTO reshaping the standard of care for hearing loss by shifting from symptomatic management with prostheses, such as hearing aids and cochlear implants, ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... according to US Bank (Wealth Management). The rapid fall surprised several investors, mainly considering ...